Clinical Trial Update: A Study to Learn More About How Well Elinzanetant Works and How Safe it is for the Treatment of Vasomotor Symptoms (Hot Flashes) That Are Caused by Hormonal Changes Over 52 Weeks in Women Who Have Been Through the Menopause [Phase 3]

View source ↗

Summary

Phase 3 study to evaluate the efficacy and safety of Elinzanetant for menopause-related vasomotor symptoms (hot flashes) over 52 weeks. Results have been posted…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hot Flashes
• Vasomotor Symptoms Associated with Menopause

Drugs mentioned

• Elinzanetant (elinzanetant)

Snippet

Sponsor: Bayer | Conditions: Vasomotor Symptoms Associated With Menopause, Hot Flashes | Phase 3 | Status: COMPLETED | Results posted: 2025-12-01